- Home
- BGM vs THRD Comparison
BGM vs THRD Comparison
Compare BGM & THRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGM
- THRD
- Stock Information
- Founded
- BGM 2019
- THRD 2019
- Country
- BGM China
- THRD United States
- Employees
- BGM N/A
- THRD N/A
- Industry
- BGM
- THRD Biotechnology: Pharmaceutical Preparations
- Sector
- BGM
- THRD Health Care
- Exchange
- BGM NYSE
- THRD Nasdaq
- Market Cap
- BGM 309.0M
- THRD 335.2M
- IPO Year
- BGM 2021
- THRD 2022
- Fundamental
- Price
- BGM $9.54
- THRD $5.79
- Analyst Decision
- BGM
- THRD Strong Buy
- Analyst Count
- BGM 0
- THRD 3
- Target Price
- BGM N/A
- THRD $20.33
- AVG Volume (30 Days)
- BGM 37.0K
- THRD 255.8K
- Earning Date
- BGM 02-13-2025
- THRD 11-07-2024
- Dividend Yield
- BGM N/A
- THRD N/A
- EPS Growth
- BGM N/A
- THRD N/A
- EPS
- BGM N/A
- THRD N/A
- Revenue
- BGM N/A
- THRD N/A
- Revenue This Year
- BGM N/A
- THRD N/A
- Revenue Next Year
- BGM N/A
- THRD N/A
- P/E Ratio
- BGM N/A
- THRD N/A
- Revenue Growth
- BGM N/A
- THRD N/A
- 52 Week Low
- BGM $1.78
- THRD $5.60
- 52 Week High
- BGM $14.78
- THRD $16.94
- Technical
- Relative Strength Index (RSI)
- BGM 50.85
- THRD 21.25
- Support Level
- BGM $9.00
- THRD $5.86
- Resistance Level
- BGM $10.75
- THRD $11.78
- Average True Range (ATR)
- BGM 1.28
- THRD 0.91
- MACD
- BGM -0.14
- THRD -0.49
- Stochastic Oscillator
- BGM 17.67
- THRD 3.11
About BGM QILIAN INTERNATIONAL HLDG GROUP LTD
BGM Group Ltd formerly, Qilian International Holding Group Ltd is a biopharmaceuticals, bio-extraction, and medical health business. Its product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium.
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.